心臟再同步治疗市场规模、份额、成长分析、按产品、按应用、按最终用户、按地区 - 行业预测，2024-2031 年

2022年全球心臟再同步治疗市场规模估值为41亿美元，从2023年的42.9亿美元增长到2031年的61.5亿美元，在预测期内（2024-2031年）预计复合年增长率为4.6。 %。

由于目标疾病盛行率上升、心臟病盛行率急剧上升、治疗投资增加以及医疗保健支出增加，心臟再同步治疗市场预计将成长。此外，技术进步、医疗设备现代化、新兴市场扩张以及老年人口的增加进一步推动了市场成长。然而，不利的医疗改革、手术部位感染风险增加以及设备敏感性增加等挑战可能会限制这种增长，并且是预测期内需要解决的障碍。了解这些动态对于寻求驾驭不断变化的市场格局的相关人员至关重要。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

按产品分類的心臟再同步治疗市场规模及复合年增长率（2024-2031）

• 市场概况
• 心臟再同步治疗心臟去颤器
• 心臟再同步治疗心律调节器

按应用分類的心臟再同步治疗市场规模和复合年增长率（2024-2031）

• 市场概况
• 室内不同步
• 室间 (VV) 非同步
• 房室 (AV) 非同步

按最终用户分類的心臟再同步治疗市场规模和复合年增长率（2024-2031）

• 市场概况
• 医院和心臟中心
• 门诊手术中心
• 其他的

心臟再同步治疗市场规模及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• Abbott Laboratories（USA）
• BIOTRONIK SE & Co. KG（Germany）
• Lepu Medical Technology Co., Ltd.（China）
• MicroPort Scientific Corporation（China）
• LivaNova PLC（UK）
• Medico SpA（Italy）
• Nihon Kohden Corporation（Japan）
• Koninklijke Philips NV（Netherlands）
• Japan Lifeline Co., Ltd.（Japan）
• Shree Pacetronix Ltd.（India）
• Integer Holdings Corporation（OSCOR Inc.）（USA）
• Osypka Medical GmbH（Germany）
• St. Jude Medical, Inc.（acquired by Abbott）（USA）
• Accellent Inc.（USA）
• Cameron Health（acquired by Emerson Electric Co.）（USA）
• Sorin Group（acquired by LivaNova）（Italy）
• Guidant Corporation（acquired by Boston Scientific）（USA）
• Cyberonics, Inc.（acquired by Abbott）（USA）

结论和建议

Global Cardiac Resynchronization Therapy Market size was valued at USD 4.1 billion in 2022 and is poised to grow from USD 4.29 billion in 2023 to USD 6.15 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031).

The cardiac resynchronization therapy market is poised for growth, driven by a rising incidence of target diseases, a surge in heart attack prevalence, increased investment in treatment, and growing healthcare expenditures. Additionally, advancements in technology, modernization of medical equipment, expansion into emerging markets, and a growing geriatric population will further propel market growth. However, challenges such as unfavorable healthcare reforms, heightened risks of surgical site infections, and high sensitivity of devices could restrain this growth, presenting hurdles that need to be addressed during the forecast period. Understanding these dynamics will be crucial for stakeholders looking to navigate the evolving landscape of the cardiac resynchronization therapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Resynchronization Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiac Resynchronization Therapy Market Segmental Analysis

Global Cardiac Resynchronization Therapy Market is segmented by product, application, end user and region. Based on product, the market is segmented into cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers. Based on application, the market is segmented into intraventricular desynchrony, interventricular (V-V) desynchrony and atrioventricular (A-V) desynchrony. Based on end user, the market is segmented into hospitals & cardiac centers, ambulatory surgery centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiac Resynchronization Therapy Market

The Global Cardiac Resynchronization Therapy market is significantly driven by the escalating prevalence of cardiovascular diseases, which continue to pose a serious health challenge worldwide. Sudden cardiac death accounts for nearly half of all fatalities linked to cardiovascular conditions, underscoring the urgent need for effective interventions. Despite advancements in treatment options, the incidence of heart diseases and associated risk factors is on the rise, leading to an increased demand for cardiac resynchronization therapy devices. With heart failure being one of the primary causes of mortality globally, the necessity for innovative therapies is more critical than ever, prompting growth in this market.

Restraints in the Global Cardiac Resynchronization Therapy Market

A significant restraint in the Global Cardiac Resynchronization Therapy market is the issue of product recalls, which can affect consumer confidence and market growth. For example, Boston Scientific Corporation initiated a recall of its INGENIO family of pacemakers and CRT-Ps in June 2022, which included models like the ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL. These devices were distributed in the U.S. between November 2016 and August 2022, having been manufactured from September 2016 to December 2018, totaling around 48,000 units. The recall was prompted by concerns that the devices could inadvertently enter safety mode, posing risks to patients' well-being.

Market Trends of the Global Cardiac Resynchronization Therapy Market

The Global Cardiac Resynchronization Therapy (CRT) market is currently experiencing significant growth driven by the rising prevalence of cardiovascular diseases and the need for effective heart failure management. CRT-Defibrillators (CRT-D), which not only promote synchronized heart contractions but also address life-threatening arrhythmias, are becoming increasingly vital in patient treatment strategies. Innovations such as smartphone connectivity and integrated applications are enhancing patient engagement and enabling remote monitoring, further augmenting their appeal. Additionally, advancements in device design, including improved battery life and MRI compatibility, are positioning CRT-D devices as critical tools in modern cardiology, reflecting a robust upward trend in this market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cardiac Resynchronization Therapy Market Size by Product & CAGR (2024-2031)

• Market Overview
• Cardiac Resynchronization Therapy Defibrillators
• Cardiac Resynchronization Therapy Pacemakers

Global Cardiac Resynchronization Therapy Market Size by Application & CAGR (2024-2031)

• Market Overview
• Intraventricular Desynchrony
• Interventricular (V-V) Desynchrony
• Atrioventricular (A-V) Desynchrony

Global Cardiac Resynchronization Therapy Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals & Cardiac Centers
• Ambulatory Surgery Centers
• Others

Global Cardiac Resynchronization Therapy Market Size & CAGR (2024-2031)

• North America (Product, Application, End User)
  • US
  • Canada
• Europe (Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOTRONIK SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lepu Medical Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medico S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Lifeline Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shree Pacetronix Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integer Holdings Corporation (OSCOR Inc.) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osypka Medical GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• St. Jude Medical, Inc. (acquired by Abbott) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accellent Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cameron Health (acquired by Emerson Electric Co.) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorin Group (acquired by LivaNova) (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guidant Corporation (acquired by Boston Scientific) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyberonics, Inc. (acquired by Abbott) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations